Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Jeffrey Dierks Sells 1,123 Shares

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) insider Jeffrey Dierks sold 1,123 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total transaction of $44,920.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Jeffrey Dierks also recently made the following trade(s):

• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07.
• On Tuesday, October 29th, Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.47, for a total transaction of $869,943.12.

Harmony Biosciences Stock Performance

Shares of NASDAQ HRMY traded up $1.41 during trading hours on Tuesday, reaching $40.46. The stock had a trading volume of 844,300 shares, compared to its average volume of 559,483. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The business's fifty day moving average is $34.46 and its two-hundred day moving average is $34.96. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61. The company has a market cap of $2.31 billion, a price-to-earnings ratio of 19.18, a PEG ratio of 0.54 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. The company had revenue of $186.00 million for the quarter, compared to analysts' expectations of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business's revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 earnings per share. As a group, research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Hedge Funds Weigh In On Harmony Biosciences

Several institutional investors have recently modified their holdings of HRMY. Citigroup Inc. lifted its stake in Harmony Biosciences by 9.8% in the 3rd quarter. Citigroup Inc. now owns 177,843 shares of the company's stock valued at $7,114,000 after acquiring an additional 15,859 shares in the last quarter. HighTower Advisors LLC raised its stake in shares of Harmony Biosciences by 364.0% during the 3rd quarter. HighTower Advisors LLC now owns 79,961 shares of the company's stock worth $3,199,000 after purchasing an additional 62,729 shares in the last quarter. Quest Partners LLC raised its stake in shares of Harmony Biosciences by 137.6% during the 3rd quarter. Quest Partners LLC now owns 35,723 shares of the company's stock worth $1,429,000 after purchasing an additional 20,689 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Harmony Biosciences by 145.4% during the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company's stock worth $9,220,000 after purchasing an additional 181,092 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Harmony Biosciences by 68.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company's stock worth $9,217,000 after purchasing an additional 93,622 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Oppenheimer reaffirmed an "outperform" rating and issued a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Raymond James restated an "outperform" rating and set a $40.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 10th. Needham & Company LLC restated a "buy" rating and set a $52.00 price objective on shares of Harmony Biosciences in a research note on Monday, January 13th. Mizuho raised their target price on Harmony Biosciences from $42.00 to $52.00 and gave the company an "outperform" rating in a research note on Thursday, October 10th. Finally, HC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Harmony Biosciences in a research note on Thursday, January 16th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Harmony Biosciences presently has an average rating of "Buy" and a consensus target price of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.